

Inhibition of Ocular Tumor and Endothelial Cell Growth with a TEAD4₂₁₆ Peptide Fragment

Bissan Ahmed^{5,*}, Andrew Stempel¹, Trevor J. McFarland¹, Bruce Ksander², Binoy Appukuttan³ and Tim Stout⁴

¹Casey Eye Institute, OHSU, Portland

²Schepens Eye Research Institute, Harvard Medical School, Boston, MA

³Flinders University, SA, Australia

⁴Cullen Eye Institute, Baylor College of Medicine Houston, TX, US

⁵Arab International University, Daraa, Syria

Abstract: *Purpose:* Transcriptional enhancer factor 1-related (RTEF-1) also known as TEAD4 is expressed in ocular vascular endothelial cells and plays a role in the control of VEGF expression. Alternative processing of TEAD4 hnRNA results in different proteins able to stimulate or inhibit VEGF gene transcription. The purpose of this study is to test whether short peptide fragments (STY-RMR), representing functional domains of the inhibitory TEAD4₂₁₆ isoform, can inhibit tumor as well as endothelial cell proliferation.

Experimental Design: Cell proliferation was assessed using a colorimetric assay in cell lines incubated with STY-RMR, the amount of secreted VEGF within media was determined both in treated and control cell lines.

Results: Significant dose dependent inhibition of cell proliferation was observed. Maximal inhibition of ocular melanoma (Mel 202 and Mel 207) cell proliferation was observed at a dose of 30 mg/100ml of STY-RMR (87% and 60% inhibition, respectively). At the same dose, more than 50% inhibition was observed in retinoblastoma and breast cancer cells (P <0.001). Significant inhibition of primate ocular endothelial cell proliferation (42% at 30 mg/100 ml (p < 0.001), and retinal pigment epithelial cells showed also a 75% inhibition (p = 0.007). Secreted VEGF was decreased in the media of all tested cell lines that had been exposed to STY-RMR.

Conclusion: Functional short peptide domains derived from the TEAD4₂₁₆ isoform may prove to be useful for treatment of ocular tumors and other VEGF dependent neovascular disease.

Inhibition of proliferation and VEGF production within ocular endothelial cells indicate the potential of this agent to treat age-related macular degeneration (ARMD) and diabetic retinopathy (DR).

Keywords: Ocular tumors, Age-related macular degeneration (ARMD), Diabetic retinopathy, STY-RMR, Endothelial cell.

INTRODUCTION

Solid tumors depend on the formation of new blood vessels from preexisting vessels to supply them with nutrients and oxygen in order to grow beyond a size of 1–2 mm³ [1]. In addition to the need for an expanding vascular network, evidence suggests that some tumor cell proliferation can be directly influenced by VEGF auto-regulation. Angiogenesis is a complex multistep process which starts with vascular endothelial growth factor (VEGF) induced vasodilatation and increased vascular permeability of pre-existing capillaries, or post-capillary venules [2].

Transcriptional enhancer factor 1-related (TEAD4) is present within ocular vascular endothelial cells and

plays a role in the control of the transcription of the VEGF gene [3]. Full-length TEAD4 is known to stimulate cell proliferation *in vitro*. In cancer biology, internal hypoxic conditions are a common feature of solid tumors [4–6], gene transcripts associated with cancer metastasis are up regulated under hypoxic conditions and hypoxic gene signatures are associated with poorer prognosis [7]. Hypoxia-induced genes like VEGF-A are set on initiating tumor vascularization [8]. TEAD4 plays an important role in transcriptional regulation of angiogenic genes in hypoxic endothelial cells and independent of HIF-1 α [9]. However, other studies suggest that TEAD4 act via HIF-1 as a key regulator of angiogenesis in response to hypoxia [10].

We have previously shown that various TEAD4 domain is the only domain present in the inhibitor TEAD4₂₁₆ and absent in the stimulator TEAD4₁₄₈, therefore we hypothesized that this small fragment of

*Address correspondence to this author at the Arab International University, Daraa, Syria;
Tel: 963 930400048; Fax: 963 116119340;
E-mail: ahmed.bissan1969@gmail.com

26 amino acids may mediate this inhibitory effect. This STY domain was linked to a cell penetrating peptide motif (RMR) to test the potential of this agent to inhibit tumor cell proliferation *in vitro*. We have previously demonstrated isoforms (generated through alternative hnRNA splicing) may be stimulatory (TEAD4₁₄₈) or inhibitory (TEAD4₂₁₆) to cell proliferation. A Ser-Thr-Tyr (STY) that a variety of human tumors expressed isoforms of TEAD4, therefore our purpose was to test whether a short peptide fragment, representing functional domains of the 651 TEAD4₂₁₆ isoform, can inhibit tumor and endothelial cell proliferation.

METHODS

A 26 amino acid sequence corresponding to a Ser-Thr-Tyr domain within TEAD4₂₁₆ (Figure 1), linked to a 10 amino acid cell importation signal (RMR) was synthesized (GenScript NJ). Human ocular melanoma cells (Mel 270, Mel 202; a kind gift from Dr Bruce Ksander), retinoblastoma cells (Y79; ATCC, MD), primate retina/choroid ocular endothelial cells (RF/6A; ATCC, MD) and human retinal pigment epithelial cells (ARPE19; ATCC, MD), (CRL 1500 breast cancer cell line; ATCC, MD) were plated into 96 well plates and cultured for 24 h. Recombinant STY-RMR peptide was added to the cell culture media at various concentrations (10 to 30 mg /100ml).

Cell proliferation was assessed at 72 hours using a colorimetric XTT assay (Roche Diagnostics, Indianapolis, and CN, USA). Cell proliferation was expressed as a percentage and compared with untreated control cell growth (n = 3).


The amount of VEGF within media was determined by VEGF ELISA (R&D Systems, MN, USA) and compared between STY-RMR treated and controls (n = 3).

RESULTS

To test whether the STY domain alone (which is present within the TEAD4₂₁₆ repressor isoform but absent from the TEAD4₁₄₈ enhancer isoform) can mediate repressor activity we synthesized STY linked to a cell penetrating peptide derived from tat (RMR) (Gen Script NJ) (Figure 1).

Transcription enhancer factor 1-related (TEAD4) is a member of the TEAD DNA binding domain family, and it is present within ocular vascular endothelial cells and plays a role in the control of VEGF expression. We have demonstrated that a variety of human tumors expressed isoforms of TEAD4 (Figure 2).

Breast cancer cells (CRL 1500) showed a very significant inhibition of 87% (P= 0.000002) at (30 ug/ 100 ul) compared with untreated controls, the



* Figures are not scale

Figure 1: The second STY domain is present within the TEAD4₂₁₆ repressor isoform but absent from the TEAD4₁₄₈ enhancer isoform. To test whether the STY domain alone can mediate repressor activity we synthesized STY linked to a cell penetrating peptide derived from tat (RMR). The STY domain is 26 amino acids and the RMR is 10 amino acids in length, making the STY-RMR peptide 36 amino acids long.




Figure 2: Variety of human tumors expressed isoforms of TEAD4.




Figure 3: Breast cancer cells (CRL 1500) showed a very significant inhibition of 87% (P= 0.000002) at (30 ug/ 100 ul) compared with untreated controls, the mean results of 3 independent experiments are shown (±SEM).

mean results of 3 independent experiments are shown (±SEM) in (Figure 3), and the proliferation of retinoblastoma cells is also inhibited by STY-RMR peptide in a dose dependent manner. We observed 85% inhibition at 30 mg /100ml which is statistically different from control experiments in the absence of STY-RMR (P= 0. 00003). Mean results of 3 independent experiments are shown (±SEM) (Figure 4). A scrambled sequence of STY-RMR was

tested as a control and it did not show any significant inhibition in Y79 retinoblastoma cells (Figure 5).

STY-RMR can inhibit cell proliferation in two different ocular melanoma cell lines. Significant inhibition (P= 0.006) of 60% below control was also observed in Mel270 incubated at the same dose and inhibition was dose dependent (Figure 6a) and 87% inhibition was observed at 30 ug /100ml for the Mel 202




Figure 4: We observed 85% inhibition in proliferation of retinoblastoma at 30 ug /100ml which is statistically different from control experiments in the absence of STY-RMR (P= 0. 00003). Mean results of 3 independent experiments are shown (±SEM).




Figure 5: Scrambled version was tested as a control and it did not show any significant inhibition in retinoblastoma (Y79).




Figure 6(a): Significant inhibition (P= 0.006) of 60% below control was also observed in Mel 270 incubated at the same dose and inhibition was dose dependent.

cells mean results of 3 independent experiments are shown (±SEM) (p = 0. 001) (Figure 6b).

STY-RMR peptide can inhibit proliferation of ocular vascular endothelial (RF/6A) and retinal pigment




Figure 6(b): 87% inhibition was observed at 30 ug /100ml for the Mel 202 cells mean results of 3 independent experiments are shown (\pm SEM) ($p = 0.001$).

epithelial cells (ARPE-19) (Figure 7a). A (42%, $p = 0.001$) inhibition of RF-6A (Figure 7b) and 75% inhibition of ARPE-19 cells was observed with 30 mg /100ml of STY-RMR ($P = 0.007$). A dose dependent response was also observed as inhibition of cell proliferation was obtained with 3ug/100ul of treatment.

ELISA indicates that STY-RMR treatment is able to decrease secreted VEGF levels in ocular melanoma cell line 270. By STY-RMR peptide. We observed 81% reduction in VEGF levels ($p = 0.01$) at 30 mg / 100ml treatment (Figure 8).




Figure 7(a): STY-RMR peptide can inhibit proliferation of ocular vascular endothelial (RF/6A) and retinal pigment epithelial cells (ARPE-19).




Figure 7(b): A (42%, $p = 0.001$) inhibition of RF-6A and 75% inhibition of ARPE-19 cells was observed with 30 mg /100ml of STY-RMR ($P = 0.007$). A dose dependent response was also observed as inhibition of cell proliferation was obtained with 3ug/100ul of treatment.




Figure 8: ELISA indicates that STY-RMR treatment is able to decrease secreted VEGF levels in ocular melanoma cell line 270. by STY-RMR peptide. We observed 81% reduction in VEGF levels ($p= 0.01$) at 30 mg / 100ml treatment.




Figure 9: VEGF levels is inhibited in ARPE19 cells by STY-RMR peptide. An 88% reduction compared to control was observed after treatment with 30 mg /100ml ($p= 0.05$).

VEGF levels is inhibited in ARPE19 cells by STY-RMR peptide (Figure 9). An 88% reduction compared to control was observed after treatment with 30 mg /100ml ($p= 0.05$).

Levels of secreted VEGF is lower in ocular retinal-choroid derived vascular endothelial cells after treatment with STY-RMR peptide. We observed 80% inhibition of VEGF at 30mg/100ml treatment ($p= 0.03$) in (Figure 10).




Figure 10: Levels of secreted VEGF is lower in ocular retinal-choroidal derived vascular endothelial cells after treatment with STY-RMR peptide. We observed 80% at 30 mg /100ml treatment ($p= 0.03$).




Figure 11: Significant inhibition in the proliferation of cancer breast cell due to VEGF reduction by STY-RMR incubated cancer.

We further tested the potential of this agent to inhibit a breast tumor cell line at a lower range of daily doses, we focused on breast cancer to optimize conditions of delivery and efficacy.

A significant inhibitory effect could be achieved by much lower daily doses twice a day for 3 days (Figure 11), since breast cancer cell (CRL 1500) had 9% inhibition at 0.1 ug/ 100ul (p= 0.02), and 27% inhibition at 0.2, 0.5, and 1 ug/100 ul (p= 0.02, 0.017, 0.02) respectively, however this inhibition was increased to 50% at (5 and 6 ug/100ul) with much higher significance (p= 0.00002, 0.0005), indicating that this factor may have similar metronomic effect observed for chemotherapeutic agents which can inhibit tumors either by high one shot or daily small doses due to thrombospondin release which is known to be an endogenous anti-angiogenic factor, however we cannot assume that the inhibitory effect of STY-

RMR given once is a cytotoxic one at the highest dose despite the observation of a potent cell death induction at (30ug/ 100 ul) since we have also observed a significant VEGF reduction at the previous dose.

This inhibition in breast tumor cells was also associated with decreased VEGF levels by STY-RMR 78% (p= 0.02) even at low concentration (0.1ug/100ul) (Figure 12).

DISCUSSION

Transcription enhancer factor 1-related (TEAD4) is a member of the TEAD DNA binding domain family, and it is present within ocular vascular endothelial cells and plays a role in the control of VEGF expression [3], it has been previously suggested that members of the TEAD family might play a role in mammary tumor genesis [11]. We have demonstrated that a variety of




Figure 12: Significant inhibition of VEGF by STY-RMR incubated cancer breast cell.

human tumors expressed isoforms of TEAD4, therefore we were motivated to test the therapeutic potential of such isoforms to treat cancer.

The full-length TEAD4 is known to stimulate cell proliferation *in vitro*, and we have shown that various TEAD4 isoforms (generated through alternative hnRNA splicing) may be stimulatory or inhibitory to cell proliferation. A Ser-Thr-Tyr (STY) domain is the only domain present in the inhibitor TEAD4₂₁₆ isoform while absent in the stimulator TEAD4₁₄₈, therefore we hypothesized that this small fragment of 26 amino acids mediates this inhibitory effect. This STY domain was linked to a cell penetrating peptide motif (RMR) to test the potential of this agent to inhibit tumor cell proliferation *in vitro*.

The activity of several anti-angiogenic proteins such as Endostatin is mimicked by a 27-amino-acid peptide [12] and it is recently developed as Fc-Endostatin which showed similar inhibition activity to this tested peptide [13] indicating that short functional domains have therapeutic potential.

Ocular melanoma and retinoblastoma (Rb) are intraocular tumors whose growth are influenced by concomitant expression of VEGF, it has been reported that the number of ocular micrometastasis is correlated with the levels of VEGF in the serum [14]. Avastin is known to suppress the growth and hepatic metastasis of uveal melanoma through VEGF inhibition therefore VEGF can be used as a prognostic factor for ocular melanoma [15] but not for retinoblastoma [16]. RF-6A (a retinal endothelial cell line) and ARPE-19 (a retinal pigment epithelium cell line) are ocular derived cell lines whose growth are VEGF-dependent [17].

Significant inhibition of cell proliferation was observed with this STY-RMR in several tumor cell lines. Dose dependent responses were noted, however the range of this inhibitory effect is tumor type and /or cell line specific We tested the potential of this agent to inhibit tumor cell lines at a lower range of daily doses, a very significant inhibitory effect could be achieved by much lower daily doses for 3 days indicating that this factor may have similar metronomic effect observed for chemotherapeutic agents which can inhibit tumors either by high single dose or daily small doses such as that observed with thrombospondin release [18-20].

An inhibitory effect on cell proliferation was noted with the STY-RMR peptide in human Y79 retinoblastoma cells a suspension cell line. the effect

was lost when the cells were exposed to the scrambled peptide at the same dose indicating that the sequence order of the STY domain is critical to the function. The efficacy of STY-RMR to inhibit tumor cells which are growing in suspension suggests this compound may prove to be therapeutic on metastatic cells in the circulation or non-solid cancers such as leukemia.

We further questioned whether STY-RMR inhibits the levels of VEGF in the same studied cell lines (ocular melanoma, RF-6A, ARPE-19, and breast cancer). We observed a significant decrease of VEGF production within different cell lines which indicates the potential of this agent to treat angiogenic diseases.

CONCLUSION

We have demonstrated that a small peptide which contains the STY motif of the human TEAD4 protein, when linked with a cell penetration motif, is able to inhibit cell proliferation rates in a number of cell lines germane to human disease. This effect is associated with a decreased rate of VEGF synthesis and may prove therapeutically useful.

FUNDING

Clayton Foundation for Research; National Institutes of Health (R01 EY019042)

REFERENCES

- [1] Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov.* 2007; 6(4): 273-86. <https://doi.org/10.1038/nrd2115>
- [2] Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. *cytogfr.* 2014.07.009. Epub 2014 Jul 23.
- [3] Appukuttan B, McFarland TJ, Davies MH, Atchaneeyasakul LO, Zhang Y, Babra B, Pan Y, Rosenbaum JT *et al.* *Invest Ophthalmol Vis Sci* 2007; 48(8): 3775-82. <https://doi.org/10.1167/iovs.06-1172>
- [4] Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. *Int J Clin Oncol.* 2012 Feb 18.
- [5] Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF) -1 inhibitors. *Eur J Med Chem* 2012; 49: 24-40. <https://doi.org/10.1016/j.ejmech.2012.01.033>
- [6] Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. *Radiother Oncol* 2011; 101(1): 190-7. Epub 2011 Jun 29. <https://doi.org/10.1016/j.radonc.2011.05.059>
- [7] Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. *Semin Radiat Oncol* 2012; 22(2): 119-27. <https://doi.org/10.1016/j.semradonc.2011.12.006>

- [8] Ferrara N. VEGF as a therapeutic target in cancer. *Oncology*. 2005; 69Suppl 3: 11-6. Epub 2005 Nov 21. <https://doi.org/10.1159/000088479>
- [9] Cuili Zhang a,b,c, QH. Song c, Jian Li c*, Ye Tian a,d,*Retraction notice to "Hypoxia-induced expression of RTEF-1 (related transcriptional enhancer factor-1) in endothelial cells is independent of HIF-1 (hypoxia inducible factor-1)" *Biochem Biophys Res Commun* 2009; 381(3): 333-338. <https://doi.org/10.1016/j.bbrc.2009.02.083>
- [10] Zhang C, Song QH, Li J, Tian Y. Hypoxia-induced expression of RTEF-1 (related transcriptional enhancer factor-1) in endothelial cells is independent of HIF-1 (hypoxia-inducible factor-1). *Biochem Biophys Res Commun*. 2009; 381(3): 333-8. Epub 2009 Feb 21. <https://doi.org/10.1016/j.bbrc.2009.02.083>
- [11] Maeda T, Maeda M, Stewart AF. TEF-1 transcription factors regulate activity of the mouse mammary tumor virus LTR. *Biochem Biophys Res Commun* 2002; 296(5): 1279-85. [https://doi.org/10.1016/S0006-291X\(02\)02085-5](https://doi.org/10.1016/S0006-291X(02)02085-5)
- [12] Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. *Cancer Res*. 2005; 65(9): 3656-63. <https://doi.org/10.1158/0008-5472.CAN-04-1833>
- [13] Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD *et al*. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. *Clin Cancer Res* 2008; 14(5): 1487-93. <https://doi.org/10.1158/1078-0432.CCR-07-1530>
- [14] Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE. Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. *Br J Ophthalmol* 2011; 95(1): 112-7. <https://doi.org/10.1136/bjo.2010.182402>
- [15] Schuster C1,2, Akslen LA1,3, Stokowy T4,5, Straume O1,2. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. 2018; 18. <https://doi.org/10.1002/cjp2.116>
- [16] Areán C, Orellana ME, Abourbih D, Abreu C, Pifano I, Burnier MN Jr. Expression of vascular endothelial growth factor in retinoblastoma. *Arch Ophthalmol* 2010; 128(2): 223-9. <https://doi.org/10.1001/archophthalmol.2009.386>
- [17] Obert E, Strauss R, Brandon C, Grek C, Ghatnekar G, Gourdie R, Rohrer B. Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology. *J Mol Med (Berl)* 2017; 95(5): 535-552. <https://doi.org/10.1007/s00109-017-1506-8>
- [18] Matsuki K, Tanabe A, Hongo A, Sugawara F, Sakaguchi K, Takahashi N *et al*. Anti-angiogenesis effect of 3'-sulfoquinovosyl-1'-monoacylglycerol via up regulation of thrombospondin 1. *Cancer Sci* 2012; 103(8): 1546-52. <https://doi.org/10.1111/j.1349-7006.2012.02333.x>
- [19] Maloney SL, Sullivan DC, Suchting S, Herbert JM, Rabai EM, Nagy Z, Barker J *et al*. Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dextrazoxane. *Br J Cancer* 2009; 101(6): 957-66. <https://doi.org/10.1038/sj.bjc.6605203>
- [20] Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. *Cancer Lett* 2008; 267(1): 26-36. <https://doi.org/10.1016/j.canlet.2008.03.008>

Received on 13-07-2018

Accepted on 25-09-2018

Published on 10-10-2018

<http://dx.doi.org/10.15379/2413-7308.2018.05.01>© 2018 Ahmed *et al.*; Licensee Cosmos Scholars Publishing House.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.